Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US
Shots:
- The approval is based on P-III KATHERINE study results assessing Kadcyla versus Herceptin in patients with HER2+ early breast cancer (eBC) with the residual invasive disease after neoadjuvant treatment included Herceptin and taxane-based CT
- The P-III KATHERINE study results: reduction in risk of breast cancer recurrence (50%); @3yrs. iDFS (88.3% vs 77.0%); absolute improvement (11.3%); worse prognosis in patients with residual disease after neoadjuvant treatment
- Kadcyla (trastuzumab emtansine) is an ADC- a combination of trastuzumab and DM1- delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com